MONQ sold unapproved inhalation essential oil products with claims to treat opioid addiction and withdrawal, FDA and FTC said.
What happened
FDA reviewed MONQ's website in May 2022 and FTC reviewed it in June 2022 and found orders for inhalation essential oil products. The site claimed ingredients such as lavender, ylang ylang, eucalyptus, cinnamon, ginger, peppermint, bergamot, lemon, and rosemary help treat opioid addiction and withdrawal and other conditions. FDA said the products are unapproved new drugs and that oral inhalation raises safety concerns.
What FDA found
The products are unapproved new drugs because they are sold with claims to treat opioid addiction and withdrawal and other diseases without FDA approval.
Federal Food, Drug, and Cosmetic Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The products are drugs because the website claims they diagnose, cure, mitigate, treat, or prevent disease or affect the body's structure or function.
Federal Food, Drug, and Cosmetic Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are new drugs not generally recognized as safe and effective for the claimed uses.
Federal Food, Drug, and Cosmetic Act section 201(p), 21 U.S.C. 321(p)FTC says advertising that an essential oil product can treat addiction requires competent and reliable scientific evidence, which FTC says does not exist for these products.
FTC Act, 15 U.S.C. §§ 41–57FTC says deceptive claims about treating substance use disorder can bring civil penalties.
Opioid Addiction Recovery Fraud Prevention Act of 2018, 15 U.S.C. § 45d
What FDA wants
FDA asks MONQ to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence. FTC asks MONQ to notify its contact within 15 working days of actions taken to address FTC's concerns.
Who should pay attention
- retailers and online marketplaces selling aromatherapy products
- companies making health or addiction-treatment claims for inhaled products
- brands using essential oil ingredients with drug-like claims
This is a summary. Read the original letter on fda.gov.